Global Antifibrinolytic Drugs Market (2019 to 2026) – Opportunity Analysis and Industry Forecast – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Antifibrinolytic Drugs Market by Indication and End user: Global Opportunity Analysis and Industry Forecast, 2019-2026” report has been added to ResearchAndMarkets.com’s offering.

The global antifibrinolytic drugs market was valued at $1,3593 million in 2018 and is expected to reach $1,9333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026.

Antifibrinolytic is a type of drug that helps in the formation of blood clot. These drugs prevent the breakdown of fibrin, which is the main protein involved in blood clotting. These drugs can be used to prevent serious bleeding in patients suffering from life threatening conditions such as hemophilia, very heavy menstrual bleeding, or some types of vascular tumors. They are also widely used to prevent or control bleeding during or after a surgery or after a traumatic injury. An increase in usage of these drugs has been witnessed since past few years, owing to their increased applications.

Rise in medical a surgeries including dental and cardiac, accidental trauma, and increase in incidence of angioedema across the globe are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a crucial role in the prevention of clot lysis and blood loss. Considerable a surge in prevalence of bleeding disorders propels the antifibrinolytic drugs market growth. However, high cost of these drugs hamper the market growth. Furthermore, increase in research & development for developing novel innovative antifibrinolytic drugs is anticipated to create new opportunities for the market.

The market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, a surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings of the Study:

• By indication, the gynecology segment accounted for the highest Antifibrinolytics Drug Market share of 28% in 2018, and is anticipated to grow at the fastest rate during the forecast period.
• By region, North America was the major shareholder and accounted for the highest share of 42% in 2018.
• Asia-Pacific is expected to grow at a CAGR of 6.1% during the forecast period.
• By end user, the hospital & clinics segment dominated the market in 2018 and is anticipated to maintain its dominance during the forecast period.
• Comprehensive competitive analysis and profiles of major market players such as Acic Fine Chems, Xanodyne Pharmaceuticals, Aurobindo Pharma Ltd., Akorn, Amerigen Pharms Ltd, Mylan, Pfizer (GenMed), Sanofi, Zydus Cadila and Takeda are provided in this report.
  

Key Topics Covered:

1. Introduction

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

1.4. Research Methodology

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

2. Executive Summary

2.1. Key Findings of The Study

2.2. CXO Perspective

3. Market Overview

3.1. Market Definition And Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.3. Porter’S Five Forces Analysis

3.3.1. Moderate Bargaining Power of Buyers

3.3.2. Low Bargaining Power of Suppliers

3.3.3. Moderate Threat of Substitutes

3.3.4. Low Threat of New Entrants

3.3.5. Moderate Competitive Rivalry

3.4. Top Player Positioning

3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. Surge In Severe Road Accidents

3.5.1.2. Significant Increase In Surgical Procedures

3.5.2. Restraint

3.5.2.1. High Cost of These Drugs

3.5.3. Opportunity

3.5.3.1. Various Growth Opportunities In Emerging Economies

4. Antifibrinolytic Drugs Market, By Indication

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Gynecology

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast

4.2.3. Market Share Analysis, By Country

4.3. Hereditary Angioedema

4.3.1. Key Market Trends And Growth Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Share Analysis, By Country

4.4. Fibrinolytic Response Testing

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Share Analysis, By Country

4.5. Surgeries

4.5.1. Key Market Trends And Opportunities

4.5.2. Market Size And Forecast

4.5.3. Market Share Analysis, By Country

4.6. Others

4.6.1. Key Market Trends And Opportunities

4.6.2. Market Size And Forecast

4.6.3. Market Share Analysis, By Country

5. Antifibrinolytic Drugs Market, By End User

5.1. Overview

5.2. Hospitals

5.3. Ambulatory Surgery Centers

5.4. Trauma Centers

6. Antifibrinolytic Drugs Market, By Region

6.1. Overview

6.1.1. Market Size And Forecast

6.2. North America

6.3. Europe

6.4. Asia-Pacific

6.5. LAMEA

7. Company Profiles

7.1. Akorn Inc.

7.2. Aurobindo Pharma Limited

7.3. Bayer Ag

7.4. Ferring Holding Sa

7.5. Mylan N.V.

7.6. Novartis International Ag (Sandoz)

7.7. Pfizer Inc.

7.8. Sanofi S.A.

7.9. Takeda Pharmaceutical Company Limited

7.10. Vitruvias Therapeutics Inc.

For more information about this report visit https://www.researchandmarkets.com/r/a6133w

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900